HC Wainwright Has Positive Outlook for ELVN FY2026 Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) – Research analysts at HC Wainwright upped their FY2026 earnings per share estimates for Enliven Therapeutics in a research note issued on Friday, November 13th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.62) per share for the year, up from their prior estimate of ($1.74). HC Wainwright currently has a “Buy” rating and a $73.00 target price on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.67) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.48) EPS and FY2027 earnings at ($1.80) EPS.

Other analysts have also issued reports about the stock. Morgan Stanley initiated coverage on shares of Enliven Therapeutics in a research note on Friday, October 2nd. They set an “overweight” rating and a $70.00 price objective for the company. Stifel Nicolaus upped their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. assumed coverage on shares of Enliven Therapeutics in a research note on Thursday, October 1st. They issued an “overweight” rating and a $75.00 target price on the stock. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.44.

View Our Latest Analysis on Enliven Therapeutics

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $44.89 on Tuesday. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $62.32. The firm’s 50-day moving average is $45.69 and its 200 day moving average is $43.98. The stock has a market cap of $3.30 billion, a price-to-earnings ratio of -26.25 and a beta of 0.34.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.09.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ELVN. BlackRock Inc. bought a new position in Enliven Therapeutics during the second quarter valued at approximately $221,255,000. First Light Asset Management LLC grew its position in Enliven Therapeutics by 574.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after purchasing an additional 1,158,883 shares during the period. Pictet Asset Management Holding SA grew its position in Enliven Therapeutics by 14.1% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,325,740 shares of the company’s stock worth $60,772,000 after purchasing an additional 163,956 shares during the period. Marshall Wace LLP grew its position in Enliven Therapeutics by 117.1% in the 3rd quarter. Marshall Wace LLP now owns 1,155,392 shares of the company’s stock worth $52,963,000 after purchasing an additional 623,123 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Enliven Therapeutics by 276.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock worth $52,898,000 after purchasing an additional 847,399 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares in the company, valued at $1,462,240. This represents a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 25,036 shares of company stock valued at $1,141,289. 3.00% of the stock is owned by insiders.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.

Featured Articles

Earnings History and Estimates for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.